Clinical Trial Update: Phase I/II Randomized Study of NBTXR3 Activated by Abscopal or RadScopal Radiation in Combination With Immunotherapy (Anti-PD-1/L-1) for Patients With Advanced Solid Malignancies [Phase 1, Phase 2]

View source ↗

Summary

This ClinicalTrials.gov update describes a Phase I/II randomized study evaluating NBTXR3 activated by abscopal or RadScopal radiation in combination with anti-P…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Liver Cancer
• Lung Cancer
• Solid Tumors

Drugs mentioned

• Anti-PD-1/PD-L1 inhibitor
• NBTXR3 (hafnium oxide nanoparticles)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Advanced Malignant Solid Neoplasm, Metastatic Malignant Neoplasm in the Liver | Phase 1, Phase 2 | Status: RECRUITING